From Financial Modeling Prep: 2025-05-27 11:00:00

AnaptysBio, Inc. (NASDAQ:ANAB) is a biotechnology company developing antibody therapeutics for inflammation and immuno-oncology. Facing competition from peers like Deciphera Pharmaceuticals, Crinetics Pharmaceuticals, Rhythm Pharmaceuticals, Kura Oncology, and CytomX Therapeutics.

AnaptysBio’s ROIC of -26.40% compared to its WACC of 13.27% results in a ROIC to WACC ratio of -1.99, indicating challenges in generating positive returns. Deciphera Pharmaceuticals, Crinetics Pharmaceuticals, and Rhythm Pharmaceuticals also struggle with negative ROICs and low ROIC to WACC ratios.

Kura Oncology shows difficulties with a ROIC of -31.40% and a ROIC to WACC ratio of -4.81. In contrast, CytomX Therapeutics stands out with a positive ROIC of 66.72% and a ROIC to WACC ratio of 7.42, demonstrating effective capital utilization.



Read more at Financial Modeling Prep:: AnaptysBio, Inc. (NASDAQ:ANAB) Financial Performan…